

Correction

Open Access

A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting – rationale, design and baseline characteristics

Caroline Laurence*¹, Angela Gialamas¹, Lisa Yelland², Tanya Bubner¹, Philip Ryan², Kristyn Willson², Briony Glastonbury³, Janice Gill⁴, Mark Shephard⁵, Justin Beilby⁶ and for members of the PoCT Trial Management Committee

Address: ¹Discipline of General Practice, The University of Adelaide, Adelaide, South Australia, Australia, ²Discipline of Public Health, The University of Adelaide, Adelaide, South Australia, Australia, ³Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia, ⁴RCPA Quality Assurance Programs Pty Ltd, Adelaide, South Australia, Australia, ⁵Community Point-of-Care Services, Flinders University Rural Clinical School, Flinders University, Adelaide, South Australia, Australia and ⁶Faculty of Health Sciences, The University of Adelaide, Adelaide, South Australia, Australia

Email: Caroline Laurence* - caroline.laurence@adelaide.edu.au ; Angela Gialamas - angela.gialamas@adelaide.edu.au ; Lisa Yelland - lisa.yelland@adelaide.edu.au ; Tanya Bubner - tanya.bubner@adelaide.edu.au ; Philip Ryan - philip.ryan@adelaide.edu.au ; Kristyn Willson - kristyn.willson@adelaide.edu.au ; Briony Glastonbury - bglastonbury@eye.usyd.edu.au ; Janice Gill - jan.gill@rcpaqap.com.au ; Mark Shephard - mark.shephard@flinders.edu.au ; Justin Beilby - Justin.beilby@adelaide.edu.au ; for members of the PoCT Trial Management Committee - caroline.laurence@adelaide.edu.au

* Corresponding author

Published: 28 January 2009

Received: 16 January 2009

Trials 2009, 10:7 doi:10.1186/1745-6215-10-7

Accepted: 28 January 2009

This article is available from: <http://www.trialsjournal.com/content/10/1/7>

© 2009 Laurence et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Following the publication of our article [1] we noticed an error within Additional file 2: Comparison of patient baseline characteristics by condition. The column headings 'Control' and 'Intervention' are incorrectly positioned in the table and should be switched.

The table should therefore appear as shown in Table 1 in this correction.

Table 1: Comparison of patient baseline characteristics by condition

Condition Group	Characteristic	Control n (%)	Intervention n (%)	Total n (%)	
Diabetes		N = 785	N = 1182	N = 1967	
	Male	432 (55.0)	651 (55.1)	1083 (55.1)	
	Age (years)	Median (IQ range)	67.0 (59.0–74.0)	66.0 (58.0–73.0)	66.0 (59.0–73.0)
	Aboriginal and Torres Strait Islander	Yes	4 (0.5)	23 (1.9)	27 (1.4)
		No	723 (92.1)	1036 (87.6)	1759 (89.4)
		Missing	58 (7.4)	123 (10.4)	181 (9.2)
	BMI	Underweight	5 (0.6)	3 (0.3)	8 (0.4)
		Normal	121 (15.4)	181 (15.3)	302 (15.4)
		Overweight	243 (31.0)	386 (32.7)	629 (32.0)
		Obese	334 (42.5)	464 (39.3)	798 (40.6)
	Missing	82 (10.4)	148 (12.5)	230 (11.7)	

Table 1: Comparison of patient baseline characteristics by condition (Continued)

HbA1c %	Median (IQ range)	7.1 (6.3–8.0)	6.9 (6.2–7.7)	7.0 (6.3–7.8)
	Missing	64 (8.2)	90 (7.6)	154 (7.8)
Diabetes management:				
Dietary control	Yes	446 (56.8)	604 (51.1)	1050 (53.4)
	No	309 (39.4)	503 (42.6)	812 (41.3)
	Missing	30 (3.8)	75 (6.3)	105 (5.3)
Insulin	Yes	145 (18.5)	204 (17.3)	349 (17.7)
	No	610 (77.7)	903 (76.4)	1513 (76.9)
	Missing	30 (3.8)	75 (6.3)	105 (5.3)
Prescription tablets	Yes	541 (68.9)	729 (61.7)	1270 (64.6)
	No	214 (27.3)	378 (32.0)	592 (30.1)
	Missing	30 (3.8)	75 (6.3)	105 (5.3)
Years since first diagnosed	< 1 year	39 (5.0)	67 (5.7)	106 (5.4)
	1–5 years	256 (32.6)	403 (34.1)	659 (33.5)
	6–10 years	201 (25.6)	235 (19.9)	436 (22.2)
	> 10 years	230 (29.3)	311 (26.3)	541 (27.5)
	Missing	59 (7.5)	166 (14.0)	225 (11.4)
Hyperlipidaemia		N = 1463	N = 2356	N = 3819
Male		753 (51.5)	1277 (54.2)	2030 (53.2)
Age (years)	Median (IQ range)	68.0 (60.0–74.0)	66.0 (58.0–74.0)	66.0 (59.0–74.0)
Aboriginal and Torres Strait Islander	Yes	9 (0.6)	26 (1.1)	35 (0.9)
	No	1342 (91.7)	2102 (89.2)	3444 (90.2)
	Missing	112 (7.7)	228 (9.7)	340 (8.9)
Index of Relative Socio-Economic Disadvantage	1 st quartile	251 (17.2)	575 (24.4)	826 (21.6)
	2 nd quartile	476 (32.5)	756 (32.1)	1232 (32.3)
	3 rd quartile	390 (26.7)	663 (28.1)	1053 (27.6)
	4 th quartile	346 (23.7)	362 (15.4)	708 (18.5)
Co-morbid conditions:				
Known heart disease	Yes	540 (36.9)	812 (34.5)	1352 (35.4)
	No	869 (59.4)	1398 (59.3)	2267 (59.4)
	Missing	54 (3.7)	146 (6.2)	200 (5.2)
Diabetes		509 (34.8)	853 (36.2)	1362 (35.7)
Smoking status	Current	103 (7.0)	201 (8.5)	304 (8.0)
	Ex-smoker	644 (44.0)	1001 (42.5)	1645 (43.1)
	Never smoked	654 (44.7)	990 (42.0)	1644 (43.0)
	Missing	62 (4.2)	164 (7.0)	226 (5.9)
Total cholesterol	Median (IQ range)	4.7 (4.0–5.4)	4.6 (4.0–5.4)	4.7 (4.0–5.4)
	Missing	99 (6.8)	186 (7.9)	285 (7.5)
Triglyceride	Median (IQ range)	1.6 (1.1–2.2)	1.6 (1.2–2.2)	1.6 (1.2–2.2)
	Missing	185 (12.6)	204 (8.7)	389 (10.2)
HDL-C	Median (IQ range)	1.3 (1.1–1.6)	1.3 (1.1–1.5)	1.3 (1.1–1.6)
	Missing	239 (16.3)	515 (21.9)	754 (19.7)
Anticoagulant therapy		N = 372	N = 572	N = 944
Male		217 (58.3)	326 (57.0)	543 (57.5)
Age (years)	Median (IQ range)	73.0 (66.0–79.0)	73.0 (65.0–78.0)	73.0 (65.0–79.0)
BMI	Underweight	7 (1.9)	5 (0.9)	12 (1.3)
	Normal	90 (24.2)	165 (28.8)	255 (27.0)
	Overweight	130 (34.9)	190 (33.2)	320 (33.9)
	Obese	111 (29.8)	132 (23.1)	243 (25.7)
	Missing	34 (9.1)	80 (14.0)	114 (12.1)
Multiple co-morbidities	Yes	170 (45.7)	285 (49.8)	455 (48.2)
	No	186 (50.0)	259 (45.3)	445 (47.1)
	Missing	16 (4.3)	28 (4.9)	44 (4.7)
INR	Below target range	73 (19.6)	115 (20.1)	188 (19.9)
	Within target range	197 (53.0)	316 (55.2)	513 (54.3)
	Above target range	37 (9.9)	63 (11.0)	100 (10.6)
	Missing	65 (17.5)	78 (13.6)	143 (15.1)

References

1. Laurence C, Gialamas A, Yelland L, Bubner T, Ryan P, Willson K, Glastonbury B, Gill J, Shepard M, Beilby J, for members of the PoCT Trial Management Committee: **A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting – rationale, design and baseline characteristics.** *Trials* 2008, **9**:50.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

